Mayur Mitra, PhD, DABT

Distinguished Scientist
Genentech, Inc.
South San Francisco, California, United States

Presentation(s):

• Nonclinical Program Considerations for Peptide Safety Assessment (S02)

  Monday, November 18, 2024
  9:00 AM - 12:00 PM CT

• Peptide Safety Assessment: Current Regulatory Expectations (S02-1)

  Monday, November 18, 2024
  9:00 AM - 9:25 AM CT

• Managing Nonmutagenic Impurities in Pharmaceuticals: Emerging Science (S13)

  Tuesday, November 19, 2024
  2:00 PM - 5:00 PM CT

• Best Practices in Impurity Qualification Study Design, 3R Considerations (S13-3)

  Tuesday, November 19, 2024
  2:30 PM - 2:55 PM CT